CASI Pharmaceuticals Granted Extension Through February 17, 2026 To Regain Nasdaq Compliance

Benzinga · 2d ago

CASI Pharmaceuticals, Inc. (NASDAQ:CASI), a clinical-stage biopharmaceutical company focused on developing CID-103, a potential best-in-class, anti-CD38 monoclonal antibody for patients with organ transplant rejection and autoimmune diseases, today announced the Nasdaq Hearings Panel (the "Panel") has granted CASI's request to continued listing on the Nasdaq Stock Market (the "Nasdaq") subject to the Company regaining compliance with the Market Value of Listed Securities (MVLS) Rule 5550(b)(2) by February 17, 2026.

The Panel granted the extension after reviewing the recent efforts made by the Company, including the appointments of an experienced Chief Executive Officer and a new Non-Executive Chairman, a commitment to focus on execution of CID-103 development, execution of a convertible note purchase agreement, additional financing initiatives underway, and planned divestiture of China